Cargando…
Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa
Asia is endemic for hepatitis C virus (HCV) infection, which is the leading cause of cirrhosis, hepatic decompensation, hepatocellular carcinoma, and liver transplantation worldwide. HCV has six major genotypes and each HCV genotype has its specific geographic distribution. HCV genotypes 1, 2, 3, an...
Autores principales: | Liu, Chen-Hua, Kao, Jia-Horng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008289/ https://www.ncbi.nlm.nih.gov/pubmed/24812506 http://dx.doi.org/10.2147/IJN.S41822 |
Ejemplares similares
-
Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005) -
Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil
por: Barros, Fabio MR, et al.
Publicado: (2013) -
Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus
por: Kim, Yu Jin, et al.
Publicado: (2011) -
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
por: Liu, Chen-Hua, et al.
Publicado: (2015) -
Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection
por: Masaki, Keiichi, et al.
Publicado: (2015)